Back to Search Start Over

Distinct gene expression patterns associated with FLT3- and NRAS-activating mutations in acute myeloid leukemia with normal karyotype

Authors :
Wolfgang Hiddemann
Benedikt Brors
Björn Tews
Claudia Schoch
Kai Neben
Jasmin Müller
Meinhard Hahn
Susanne Schnittger
Felix Kokocinski
Peter Lichter
Torsten Haferlach
Roland Eils
Source :
Oncogene. 24:1580-1588
Publication Year :
2005
Publisher :
Springer Science and Business Media LLC, 2005.

Abstract

In acute myeloid leukemia (AML), constitutive activation of the FLT3 receptor tyrosine kinase, either by internal tandem duplications (FLT3-ITD) of the juxtamembrane region or by point mutations in the second tyrosine kinase domain (FLT3-TKD), as well as point mutations of the NRAS gene (NRAS-PM) are among the most frequent somatic gene mutations. To elucidate whether these mutations cause aberrant signal transduction in AML, we used gene expression profiling in a series of 110 newly diagnosed AML patients with normal karyotype. The different algorithms used for data analysis revealed highly concordant sets of genes, indicating that the identified gene signatures are specific for each analysed subgroup. Whereas samples with FLT3-ITD and FLT3-TKD could be separated with up to 100% accuracy, this did not apply for NRAS-PM and wild-type samples, suggesting that only FLT3-ITD and FLT3-TKD are associated with an apparent signature in AML. The set of discriminating genes included several known genes, which are involved in cell cycle control (CDC14A, WEE1), gene transcription (HOXB5, FOXA1), and signal transduction (SMG1). In conclusion, we showed that unique gene expression patterns can be correlated with FLT3-ITD and FLT3-TKD. This might lead to the identification of further pathogenetic relevant candidate genes particularly in AML with normal karyotype.

Details

ISSN :
14765594 and 09509232
Volume :
24
Database :
OpenAIRE
Journal :
Oncogene
Accession number :
edsair.doi.dedup.....771ffc9d8c2d7ebc90506b95dce41e5a
Full Text :
https://doi.org/10.1038/sj.onc.1208344